Rosalind Advisors
Latest statistics and disclosures from Rosalind Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DCTH, MYO, CRMD, ABEO, MDWD, and represent 43.63% of Rosalind Advisors's stock portfolio.
- Added to shares of these 10 stocks: CRMD (+$12M), Cormedix Inc call, MDWD, CLRB, Cassava Sciences Inc put, MYO, OWLT, OCUL, PYPD, VRNA.
- Started 5 new stock positions in CRMD, Cormedix Inc call, OWLT, VOR, QQQ.
- Reduced shares in these 10 stocks: CYBN (-$162M), VRDN, CLSD, ABVX, TRVI, RZLT, GERN, Annovis Bio, UNCY, SPRB.
- Sold out of its positions in ALNYLAM PHARMACEUTICALS INC. Common Stock cmn, Annovis Bio, XAIR, BTAI, G1 Therapeutics Inc put, GERN, LYRA, RZLT, SPRB, Tonix Pharmaceuticals Hldg. UNCY, VRDN.
- Rosalind Advisors was a net seller of stock by $-152M.
- Rosalind Advisors has $156M in assets under management (AUM), dropping by 20.20%.
- Central Index Key (CIK): 0001622627
Tip: Access up to 7 years of quarterly data
Positions held by Rosalind Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rosalind Advisors
Rosalind Advisors holds 33 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Delcath Systems Com New (DCTH) | 13.6 | $21M | 2.7M | 8.00 |
|
|
| Myomo Com New (MYO) | 7.8 | $12M | +13% | 3.0M | 4.01 |
|
| Cormedix Inc cormedix (CRMD) | 7.6 | $12M | NEW | 1.5M | 8.08 |
|
| Abeona Therapeutics- Com New (ABEO) | 7.4 | $12M | +4% | 1.8M | 6.32 |
|
| Mediwound Shs New (MDWD) | 7.3 | $11M | +22% | 628k | 18.06 |
|
| Cybin Ord (CYBN) | 6.1 | $9.6M | -94% | 1.1M | 8.89 |
|
| Xeris Pharmaceuticals (XERS) | 5.7 | $8.8M | 3.1M | 2.85 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 5.1 | $7.9M | +10% | 275k | 28.77 |
|
| Cellectar Biosciences Com New (CLRB) | 5.0 | $7.9M | +35% | 3.7M | 2.14 |
|
| Ocular Therapeutix (OCUL) | 4.9 | $7.7M | +18% | 885k | 8.70 |
|
| Inspiremd (NSPR) | 4.3 | $6.7M | 2.5M | 2.68 |
|
|
| Optinose (OPTN) | 3.6 | $5.6M | +9% | 8.3M | 0.67 |
|
| Compass Pathways Sponsored Ads (CMPS) | 3.2 | $4.9M | +6% | 781k | 6.30 |
|
| Profound Medical Corp Com New (PROF) | 2.5 | $3.9M | -8% | 486k | 7.96 |
|
| Cormedix Call Call Option | 2.3 | $3.6M | NEW | 700k | 5.20 |
|
| Kalvista Pharmaceuticals (KALV) | 2.3 | $3.5M | -10% | 304k | 11.58 |
|
| Trevi Therapeutics (TRVI) | 1.6 | $2.5M | -46% | 750k | 3.34 |
|
| Outlook Therapeutics Com New | 1.5 | $2.4M | 450k | 5.34 |
|
|
| Polypid (PYPD) | 1.5 | $2.3M | +62% | 679k | 3.44 |
|
| Female Health (VERU) | 1.3 | $2.1M | 2.7M | 0.77 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $1.6M | -63% | 140k | 11.52 |
|
| Cassava Sciences Put Put Option | 0.9 | $1.5M | +9902% | 367k | 3.95 |
|
| Owlet Cl A New (OWLT) | 0.8 | $1.2M | NEW | 270k | 4.49 |
|
| Kiora Pharmaceuticals Com New | 0.6 | $935k | 256k | 3.66 |
|
|
| Fortress Biotech Inc- Com New (FBIO) | 0.5 | $727k | -17% | 503k | 1.45 |
|
| Biofrontera Com New (BFRI) | 0.4 | $659k | 496k | 1.33 |
|
|
| Talphera Com New (TLPH) | 0.4 | $650k | 759k | 0.86 |
|
|
| Journey Med Corp (DERM) | 0.4 | $598k | -7% | 106k | 5.65 |
|
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 0.1 | $221k | NEW | 150k | 1.47 |
|
| Newamsterdam Pharma Co Nv Ordinary Shares (NAMS) | 0.1 | $168k | 10k | 16.60 |
|
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 0.1 | $164k | +792% | 200k | 0.82 |
|
| Clearside Biomedical (CLSD) | 0.1 | $162k | -95% | 127k | 1.27 |
|
| Vor Biopharma (VOR) | 0.0 | $54k | NEW | 77k | 0.70 |
|
Past Filings by Rosalind Advisors
SEC 13F filings are viewable for Rosalind Advisors going back to 2023
- Rosalind Advisors 2024 Q3 filed Oct. 30, 2024
- Rosalind Advisors 2024 Q2 filed July 12, 2024
- Rosalind Advisors 2024 Q1 filed April 25, 2024
- Rosalind Advisors 2023 Q4 filed Feb. 14, 2024